These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23373312)

  • 21. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.
    Richards AA; Hickman IJ; Wang AY; Jones AL; Newell F; Mowry BJ; Whitehead JP; Prins JB; Macdonald GA
    J Clin Psychopharmacol; 2006 Jun; 26(3):232-7. PubMed ID: 16702887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
    Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
    Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
    Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
    Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.
    Birkenaes AB; Birkeland KI; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2009 Apr; 29(2):109-16. PubMed ID: 19512971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
    Baptista T; Sandia I; Lacruz A; Rangel N; de Mendoza S; Beaulieu S; Contreras Q; Galeazzi T; Vargas D
    Int Clin Psychopharmacol; 2007 Mar; 22(2):69-76. PubMed ID: 17293706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.
    Atmaca M; Tezcan E; Ustundag B
    J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
    Perez-Iglesias R; Vazquez-Barquero JL; Amado JA; Berja A; Garcia-Unzueta MT; Pelayo-Terán JM; Carrasco-Marín E; Mata I; Crespo-Facorro B
    J Clin Psychopharmacol; 2008 Jun; 28(3):289-95. PubMed ID: 18480685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
    Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
    J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
    Hardy TA; Marquez E; Kryzhanovskaya L; Taylor CC; Cavazzoni P
    J Clin Psychopharmacol; 2006 Aug; 26(4):405-8. PubMed ID: 16855460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
    Reaven GM; Lieberman JA; Sethuraman G; Kraemer H; Davis JM; Blasey C; Tsuang MT; Schatzberg AF
    J Psychiatr Res; 2009 Jul; 43(11):997-1002. PubMed ID: 19268968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.